AR081024A1 - Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso - Google Patents
Asociacion de los inhibidores de la xantina oxidasa y la metformina y su usoInfo
- Publication number
- AR081024A1 AR081024A1 ARP110101591A ARP110101591A AR081024A1 AR 081024 A1 AR081024 A1 AR 081024A1 AR P110101591 A ARP110101591 A AR P110101591A AR P110101591 A ARP110101591 A AR P110101591A AR 081024 A1 AR081024 A1 AR 081024A1
- Authority
- AR
- Argentina
- Prior art keywords
- association
- metformin
- inhibitors
- oxidase
- xantine oxidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2010A000233A IT1400609B1 (it) | 2010-05-10 | 2010-05-10 | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081024A1 true AR081024A1 (es) | 2012-05-30 |
Family
ID=43519819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101591A AR081024A1 (es) | 2010-05-10 | 2011-05-09 | Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR081024A1 (it) |
CR (1) | CR20120617A (it) |
IT (1) | IT1400609B1 (it) |
TW (1) | TW201206431A (it) |
WO (1) | WO2011141419A1 (it) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202191545A1 (ru) | 2018-12-06 | 2021-10-28 | Артроси Терапьютикс, Инк. | Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии |
KR20210102933A (ko) * | 2018-12-06 | 2021-08-20 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방 방법 |
WO2024033705A1 (en) * | 2022-08-08 | 2024-02-15 | Xortx Therapeutics, Inc. | Xanthine oxidase inhibitor formulations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100221041B1 (ko) | 1990-11-30 | 1999-09-15 | 야스이 쇼사꾸 | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 |
DE69941672D1 (de) | 1998-06-19 | 2010-01-07 | Teijin Ltd | Polymorphe modifikationen der 2-(3-cyano-4-isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung |
US20040122067A1 (en) | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
EP1940397A4 (en) | 2005-08-03 | 2010-01-20 | Takeda Pharmaceuticals North A | METHOD FOR TREATING HYPERTONIA |
WO2007062028A2 (en) | 2005-11-21 | 2007-05-31 | Tap Pharmaceutical Products, Inc. | Treatment of qt interval prolongation and diseases associated therewith |
US20080269226A1 (en) | 2006-11-13 | 2008-10-30 | Christopher Lademacher | Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors |
US20100305074A1 (en) * | 2007-04-04 | 2010-12-02 | Hight H Thomas | Niacin-based pharmaceutical compositions |
US20100137289A1 (en) * | 2007-04-17 | 2010-06-03 | Johnson Richard J | Methods and Compositions for Ameliorating Thiazide Induced Hyperlipidemia |
-
2010
- 2010-05-10 IT ITRM2010A000233A patent/IT1400609B1/it active
-
2011
- 2011-05-09 WO PCT/EP2011/057412 patent/WO2011141419A1/en active Application Filing
- 2011-05-09 AR ARP110101591A patent/AR081024A1/es unknown
- 2011-05-09 TW TW100116121A patent/TW201206431A/zh unknown
-
2012
- 2012-12-06 CR CR20120617A patent/CR20120617A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201206431A (en) | 2012-02-16 |
WO2011141419A1 (en) | 2011-11-17 |
IT1400609B1 (it) | 2013-06-14 |
ITRM20100233A1 (it) | 2011-11-11 |
CR20120617A (es) | 2013-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020005887A2 (es) | Compuestos policíclicos como inhibidores alostéricos de shp2 | |
ECSP12012334A (es) | Morfolinopirimidinas y su uso en terapia | |
SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CO6430456A2 (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
CL2010001475A1 (es) | Compuestos derivados de ester boronato, inhibidores de proteasoma; composiciones farmaceuticas que los contienen; procedimiento de preparacion de la composición farmaceutica; utiles en el tratamiento de enfermedades proliferativas celulares, en particular cancer. | |
SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
CL2013001093A1 (es) | Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer . | |
CL2009001484A1 (es) | Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia. | |
CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
CL2008002916A1 (es) | Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros. | |
BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
UY31922A (es) | Compuestos | |
CL2011002675A1 (es) | Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
CL2011001777A1 (es) | Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares. | |
SV2010003773A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
AR081024A1 (es) | Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso | |
BR112014008400A2 (pt) | derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas | |
ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |